Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-10-29

Clinical Trial Update: A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating azacitidine (Vidaza) in patients with chronic myelomonocytic leukemia has completed, and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VIDAZA (AZACITIDINE)

Snippet

Sponsor: University of Utah | Conditions: Chronic Myelomonocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2015-10-29